Rongjuan Zheng

ORCID: 0000-0002-9504-1926
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Gout, Hyperuricemia, Uric Acid
  • Berberine and alkaloids research
  • Ferroptosis and cancer prognosis
  • Pharmacological Effects of Natural Compounds
  • Silymarin and Mushroom Poisoning
  • Inflammasome and immune disorders

Tangshan People's Hospital
2019

Tianjin Medical University General Hospital
2018

Tianjin Medical University
2018

Tangshan Gongren Hospital
2018

Inflammatory bowel disease (IBD), characterized by sustained inflammation, is a latent risk factor of colon tumorigenesis. Silibinin has been reported to be anti-inflammatory and antineoplastic, but its efficacy on colitis-associated cancer (CAC) not reported. Interlukin-6/signal transducer activator transcription 3 (IL-6/STAT3) the key signaling pathway involved in CAC. We evaluated chemopreventive effect silibinin CAC mouse model determined impact IL-6/STAT3 signaling. Intestinal tumor...

10.1155/2018/1562010 article EN cc-by Mediators of Inflammation 2018-10-25

Objective To investigate the efficacy of silibinin on DSS-induced colitis and its regulation for NLRP3 inflammasome. Methods A total 48 8-week-old C57BL/6 mice were randomly divided into three groups: control group, DSS group respectively. The was fed with normal chow water seven days while treated 2%DSS in drinking 0.2 ml 0.5%CMC by gavage 750 mg/kg dissolved respectively each mouse once a day days. severity colitis, function intestinal barrier activation inflammasome compared among...

10.3760/cma.j.issn.2096-367x.2019.01.015 article EN Chin J Inflamm Bowel Dis 2019-01-25
Coming Soon ...